This webinar will present the evolution of ablative dose radiation at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center over the past 20 years. Learning Objectives
• Understand how curative ablative hypofractionated treatment has evolved to MRgRT to address the limitation of the sensitivity of the surrounding mobile GI tract.
• Review the importance of treating regional disease, which is present 80% of the time, for cure.
• Examine why full doses and regional volumes must be used for treatment to become a standard competitive with surgery.
• Explore tools being developed to enhance the ability and efficiency of MRgRT delivered with Elekta Unity, including 3-D MLC tracking (MRSigma) and interfraction GI dose accumulation.